ArticleNature communications2026
Agonal cell resuscitation strategy to promote tissue repair.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overactive lytic regulated cell death (RCD) causes excessive inflammation and impairs tissue repair. Current strategies rely on small-molecule inhibitors targeting the initiation of lytic RCD but these show off-target effects and reduced pro-repair factor release. During lytic RCD, a transitional agonal stage exists between initiation and terminal death, during which cells either proceed to terminal death or undergo resuscitation. Here, we found that agonal cells actively upregulated uptake of extracellular vesicles (EVs), and internalised EVs fused with the plasma membrane via SNARE complexes to enhance membrane repair. We demonstrated that enhancing the membrane repair capacity of agonal cells through artificially prepared EV-mimetic nano-platelet vesicles (NPVs) effectively promoted their resuscitation. Moreover, resuscitated cells secreted substantial amounts of prostaglandin E2 and N1-Acetylspermidine to further promote tissue repair. Our therapeutic strategy for lytic RCD-related delayed tissue repair is based on EV-mediated membrane repair and aims to establish a pro-regenerative niche using NPVs that can drive agonal cell resuscitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.